Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $79.90 -2.56%
EPS Growth %: +4.8%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +4.8%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $2.75, $3.20 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $542.71 million versus the consensus estimate of $127.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Alphabet to replace Verizon in the Dow Jones Industrial Average
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
